Medtronic’s TYRX Neuro Absorbable Antibacterial Envelope available in US: 5 key points

Medtronic’s TYRX Neuro Absorbable Antibacterial Envelope has been successfully implanted with the company’s Deep Brain Stimulation systems in the United States.

Advertisement

Here are five key points:

 

1. Francisco Ponce, MD, of Barrow Neurological Institute in Phoenix, implanted the first TYRX Neuro envelopes.

 

2. A surgical mesh envelope, the TYRX Neuro locks an implantable neurostimulator or cardiac implantable electronic device in place.

 

3. Once implanted, it releases minocycline and rifampin over seven days to prevent surgical site infections.

 

4. Nine weeks after the implantation operation, the body completely absorbs the TRYX Neuro.

 

5. The FDA has cleared TRYX Neuro’s use with CIEDs and INS systems.

 

“The TYRX Neuro Absorbable Antibacterial Envelope is a much needed and long awaited solution to the risk of infection related to implanted neurostimulator,” said Dr. Ponce. “It is going to be the standard of care in my practice.”

 

More articles on devices:
Dr. Faheem Sandhu performs 1st FacetLINK HEMI implantation in the US: 5 key points
Global minimally invasive neurosurgery devices market on the rise: 5 things to know
Smith & Nephew’s VISIONAIRE Cutting Guides successfully used in 1st surgery in Latin America: 4 takeaways

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new technology acquisitions to regulatory clearances to leadership changes, here are 20 developments and updates from the biggest players…

  • VB Spine has made big pushes into the spine medtech space so far in 2026, including global expansions. Six headlines…

Advertisement

Comments are closed.